STOCK TITAN

Nautilus Biotechnology Stock Price, News & Analysis

NAUT NASDAQ

Company Description

Overview

Nautilus Biotechnology Inc is a development stage life sciences company pioneering a platform technology designed to quantify and unlock the complexity of the human proteome. With a foundation built on robust interdisciplinary expertise in proteomics, chip design, molecular biology, and data science, the company is redefining how the proteome is accessed and understood. By integrating advanced proteome analysis systems, reagent kits, and tailored software for deep data analytics, Nautilus is strategically positioned to enhance therapeutic development and revolutionize medical diagnostics.

Core Mission and Platform Technology

The company was created from the insightful vision of its founders, who recognized a significant gap in the field of proteomics. Nautilus Biotechnology’s core mission is to democratize access to proteomic information, thereby accelerating advancements in personalized and predictive medicine. Their state-of-the-art platform enables researchers and medical professionals to delve deeper into proteomic data, providing critical insights that can lead to refined therapeutic targets and innovative diagnostic solutions. This approach has led to the development of a comprehensive suite of products including advanced proteome analysis platforms, reagent kits, and software tools tailored for complex data analysis.

Industry Context and Competitive Position

Operating within the competitive intersection of biotechnology and life sciences, Nautilus Biotechnology navigates a challenging market where innovation and precision are paramount. With an increasing focus on personalized medicine, the company’s technology addresses a crucial need for high-resolution, reliable proteomic data. Terms such as "advanced proteomics", "therapeutic development", and "medical diagnostics" are integral to understanding the company’s market stance. Competitors in the biotechnology sphere may offer segmented solutions, but Nautilus approaches proteomics as a holistic system, ensuring that its technology not only captures intricate protein details but also translates this complexity into actionable insights for research and clinical applications.

Products and Services

  • Proteome Analysis Platform: A central component of its offering, the system is engineered to provide detailed quantification of the human proteome, enabling scientists to observe and analyze protein expressions and interactions at an unprecedented scale.
  • Reagent Kits: These are designed to support standardized and precise proteomic experiments, ensuring consistency and reproducibility throughout the research process.
  • Software and Data Analytics: Customized analytical tools and software are provided to process and interpret complex proteomic data, making it accessible for further research and innovation across therapeutic and diagnostic fields.

Operational Excellence and Interdisciplinary Expertise

The strength of Nautilus Biotechnology lies in its interdisciplinary approach, bringing together experts from diverse fields such as protein chemistry, molecular biology, chip design, and bioinformatics. This confluence of knowledge and expertise not only fuels innovation within the company but also supports its robust operational model. The integration of sophisticated hardware, advanced reagents, and high-performance software creates a seamless ecosystem that fosters scientific discovery and enhances data accuracy. Such innovations underscore the company’s commitment to providing a complete, reliable solution in the realm of proteomics.

Significance in the Broader Field

Nautilus Biotechnology has positioned itself at the very heart of the evolving field of proteomics. By transforming the way proteins are quantified and analyzed, the company has laid the groundwork for significant breakthroughs in the development of targeted therapies and the improvement of diagnostic methodologies. Its comprehensive approach not only bridges the gap between innovative biotechnology and clinical application but also opens new avenues for research. Whether it is through enhancing drug development protocols or establishing new standards in proteomic research, Nautilus serves as a pivotal contributor to the progression of modern medicine.

Conclusion

In summary, Nautilus Biotechnology Inc stands as a remarkable example of innovation within the life sciences sector. It leverages comprehensive platform technologies and a wide spectrum of interdisciplinary expertise to democratize proteomics. With its detailed focus on providing a full suite of analysis and research tools, the company addresses both immediate scientific challenges and long-standing gaps in proteomic research. Investors and market observers interested in advanced biotechnology and transformative research methodologies will find the company’s approach both groundbreaking and meticulously thought out.

Stock Performance

$0.6889
+0.07%
+0.00
Last updated: April 27, 2025 at 18:49
-44.37 %
Performance 1 year
$95.6M
Market Cap
126.1M
Shares outstanding

SEC Filings

No SEC filings available for Nautilus Biotechnology.

Financial Highlights

-$16,446,000
Net Income (TTM)
-$0.13
Diluted EPS (TTM)
-$13,113,000
Operating Cash Flow
16.65
Current Ratio
Revenue (TTM)
Net Profit Margin

Upcoming Events

April 29, 2025
Q1 2025 earnings release
April 29, 2025
Q1 2025 earnings call

Frequently Asked Questions

What is the current stock price of Nautilus Biotechnology (NAUT)?

The current stock price of Nautilus Biotechnology (NAUT) is $0.6884 as of April 25, 2025.

What is the market cap of Nautilus Biotechnology (NAUT)?

The market cap of Nautilus Biotechnology (NAUT) is approximately 95.6M.

What is the net income of Nautilus Biotechnology (NAUT)?

The trailing twelve months (TTM) net income of Nautilus Biotechnology (NAUT) is -$16,446,000.

What is the earnings per share (EPS) of Nautilus Biotechnology (NAUT)?

The diluted earnings per share (EPS) of Nautilus Biotechnology (NAUT) is -$0.13 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Nautilus Biotechnology (NAUT)?

The operating cash flow of Nautilus Biotechnology (NAUT) is -$13,113,000.

What is the current ratio of Nautilus Biotechnology (NAUT)?

The current ratio of Nautilus Biotechnology (NAUT) is 16.65, indicating the company's ability to pay short-term obligations.

What is the primary focus of Nautilus Biotechnology Inc?

Nautilus Biotechnology Inc focuses on developing a platform technology that quantifies the human proteome, facilitating advanced proteomics research and applications in therapeutic development and diagnostics.

How does Nautilus Biotechnology generate revenue?

The company operates by providing a suite of products including proteome analysis systems, reagent kits, and specialized software, which are integral to research and diagnostic applications in proteomics.

Which industries benefit from Nautilus Biotechnology's technology?

Industries such as biotechnology, pharmaceuticals, and medical diagnostics benefit from Nautilus Biotechnology's advanced solutions for proteome analysis, aiding in drug discovery and precision medicine.

How does Nautilus Biotechnology differentiate itself from competitors?

Nautilus leverages interdisciplinary expertise and a holistic approach to proteomics, combining advanced hardware, reagents, and custom software to provide a comprehensive and integrated research solution.

What makes the company’s proteome analysis system unique?

The system is uniquely designed to deliver high-resolution, precise proteomic data, enabling detailed insights into protein expressions and interactions that are critical for innovative therapeutic and diagnostic applications.

Who are the likely customers of Nautilus Biotechnology?

The company primarily serves research institutions, biotech firms, pharmaceutical companies, and clinical laboratories that require detailed proteomic analysis for advancing scientific research and medical diagnostics.